Evaluating a co-designed shared care model of care on the quality of life of patients accessing gender affirming hormone therapy

Not Applicable

• Conditions: Gender Dysphoria; Mental Health - Depression

• Registration Number: ACTRN12624000835549
• Lead Sponsor: niversity of Melbourne

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-07-05
• Last Update Posted: 15 July 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 234

Inclusion Criteria

1. Currently residing in rural or remote Victoria (Modified Monash Model Remoteness Areas 2 – 7)
2.Aged 18 years or over
3.Aged 16 – 17 and have both parents provide informed consent for the initiation of gender affirming hormone therapy and participation.
4.Have a gender that is different from what was recorded at birth (i.e. transgender or gender diverse), including binary and non-binary gender identities, or cultural gender identities
5.Have been referred to a Gender Clinic for commencement of gender affirming hormone therapy
6.Have capacity to provide informed consent
7.Able to understand and complete questionnaires
; 1. Currently residing in rural or remote Victoria (Modified Monash Model Remoteness Areas 2 – 7)
2.Aged 18 years or over
3.Aged 16 – 17 and have both parents provide informed consent for the initiation of gender affirming hormone therapy and participation.
4.Have a gender that is different from what was recorded at birth (i.e. transgender or gender diverse), including binary and non-binary gender identities, or cultural gender identities
5.Have been referred to a Gender Clinic for commencement of gender affirming hormone therapy
6.Have capacity to provide informed consent
7.Able to understand and complete questionnaires

Exclusion Criteria

- aged under 16 years
- have a gender that is congruent with what was presumed for them at birth (i.e. cisgender); - aged under 16 years
- have a gender that is congruent with what was presumed for them at birth (i.e. cisgender)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Quality of life[EQ-VAS 0, 3, 6 (primary timepoint), 12, 24 months post-enrolment];Quality of life[EQ-5D-5L 0, 3, 6 (primary timepoint), 12, 24 months post-enrolment];GP knowledge and GP confidence in transgender health[Questionnaire designed specifically for this study 0, 12 (primary timepoint), 24 months post-enrolment];Quality of life[EQ-VAS 0, 3, 6 (primary timepoint), 12, 24 months post-enrolment];Quality of life[EQ-5D-5L 0, 3, 6 (primary timepoint), 12, 24 months post-enrolment];GP knowledge and GP confidence in transgender health[Questionnaire designed specifically for this study 0, 12 (primary timepoint), 24 months post-enrolment]